Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2011-02-15
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 399
- Registration Number
- NCT00499018
- Locations
- 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2009-05-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 374
- Registration Number
- NCT00494897
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital general de Castellón, Castello, Castellón, Spain
🇪🇸Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura
- Conditions
- Interventions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT00486421
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00485303
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Beth Israel Hospital, Boston, Massachusetts, United States
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT00477750
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2012-10-16
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 2
- Registration Number
- NCT00472030
- Locations
- 🇺🇸
University of Iowa, Department of Dermatology, Iowa City, Iowa, United States
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- Office of Rare Diseases (ORD)
- Target Recruit Count
- 54
- Registration Number
- NCT00466843
- Locations
- 🇺🇸
UCLA Oncology Center, Los Angeles, California, United States
🇺🇸Penn State University, Hershey, Pennsylvania, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 108
- Registration Number
- NCT00466440
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sisto, Italy
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 88
- Registration Number
- NCT00463385
- Locations
- 🇦🇹
Medical University of Vienna, Department of Internal Medicine, Hematology, Vienna, Austria
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸New York Presbyterian HospitalWeill Medical College of Cornell University, New York, New York, United States
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00459186
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.